A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-Week EFFICACY AND SAFETY OUTCOMES FROM a RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
Proceedings article published in 2020 by
Sukanya Chaudhury,
Amanda M. Gellett,
Maja Hojnik,
Soyi Liu Leage,
Lingnan Li,
Philip Mease,
Peter Nash 
,
Sreekumar G. Pillai,
Hendrik Schulze-Koops,
Josef Smolen,
Hasan Tahir
,
Sreekumar G. Pillai,
Hendrik Schulze-Koops,
Josef Smolen,
Hasan Tahir
